Perspective Therapeutics (CATX) Stock Price
Perspective Therapeutics Price
Revenue at Perspective Therapeutics has contracted by 4.2% per year over the past 19 years to 884,000.00 USD. Perspective Therapeutics's net margin stands at -11,665.3%, down from -31.7% several years earlier. Analysts set a median price target of 2.24 USD, implying 24.7% above the current price. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.
Perspective Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Perspective Therapeutics business model & stock analysis
Frequently asked questions about Perspective Therapeutics
Analysts currently set an average price target of 2.31 USD for the Perspective Therapeutics stock (median: 2.24 USD), implying +28.1 % versus the latest price. The consensus is based on 11 analyst ratings.
21 analysts currently rate the Perspective Therapeutics stock: 19 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Perspective Therapeutics to generate revenue of 287,638.00 USD and earnings per share of -1.51 USD.
Converted at the current exchange rate, the Perspective Therapeutics share trades at 1.61 EUR (1.80 USD).
The expected revenue of Perspective Therapeutics is 287,638.00 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Perspective Therapeutics is -111.43 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Perspective Therapeutics is currently -1.19. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Perspective Therapeutics stock.
The price-to-sales ratio (P/S) of Perspective Therapeutics is currently 461.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Perspective Therapeutics stock.
The Eulerpool Quality Score for Perspective Therapeutics is 1/10.
The ISIN of Perspective Therapeutics is US46489V3024. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Perspective Therapeutics is CATX. The ticker symbol is used to trade Perspective Therapeutics shares on the stock exchange.
Perspective Therapeutics stock
Perspective Therapeutics Peer Group
All fundamentals and in-depth analysis of Perspective Therapeutics
Our stock analysis for Perspective Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Perspective Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.